Author(s):
Yudith Annisa Ayu Rezkitha, Soetjipto Soetjipto, Willy Sandhika, Juniastuti Juniastuti, Budi Utomo, Mohan Ramchandani, Phawinee Subsomwong, Hasan Maulahela, Langgeng Agung Waskito, Maria Inge Lusida, Ricky Indra Alfaray, Yoshio Yamaoka, Muhammad Miftahussurur
Email(s):
muhammad-m@fk.unair , yyamaoka@oita-u.ac.jp
DOI:
10.52711/0974-360X.2025.00758 
Address:
Yudith Annisa Ayu Rezkitha1,2,3,4,5, Soetjipto Soetjipto6, Willy Sandhika7, Juniastuti Juniastuti8,9, Budi Utomo10, Mohan Ramchandani11, Phawinee Subsomwong12, Hasan Maulahela13, Langgeng Agung Waskito4,14, Maria Inge Lusida8,9, Ricky Indra Alfaray4,5, Yoshio Yamaoka5,15,16*, Muhammad Miftahussurur4,17*
1Subspeciality Program in Hematology and Medical Oncology Division, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia.
2Subspeciality Program in Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia.
3Departement of Internal Medicine, Faculty of Medicine, Universitas Muhammadiyah Surabaya, Surabaya, Indonesia.
4Helicobacter pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.
5Department of Environmental Preventive Medicine, Faculty of Medicine, Oita University Faculty of Medicine, Yuf
Published In:
Volume - 18,
Issue - 11,
Year - 2025
ABSTRACT:
Several biomarkers could identify colorectal cancer (CRC) including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and platelet to lymphocyte ratio (PLR). However, the advantages of this biomarkers for identifying late-stage CRC still not clearly described. We assessed the value of accuracy and the relationship of biomarkers with CRC. We collected secondary data from hospital medical records between 2018-2020. We analyzed 50 complete data of CEA, 25 of CA 19-9, and 202 of PLR. We found a significant correlation between CEA with M stage (p = 0.002, AUC = 0.667), CRC stages (p = 0.021, AUC = 0.665), and metastases organs (p = 0.002, AUC = 0.667). Positive significant correlation also between CA 19-9 with M stage (p = 0.023, AUC = 0.650), CRC stages (p = 0.045, AUC = 0.697), and metastases organ (p = 0.023, AUC = 0.650). In addition, this study was reported significant correlation between PLR with metastases stage (p = 0.001, AUC = 0.620), CRC stage (p = 0.047, AUC = 0.576) and metastases organ (p = 0.003, AUC = 0.604). CEA, CA 19-9, and PLR are not suitable for confirming the presence of CRC, particularly when determining its stage and metastasis. However, they can be valuable for identifying individuals who do not have CRC, allowing for the establishment of a negative classification. When trying to detect CRC cases, CEA and CA 19-9 can be used independently as markers, while PLR should be used in combination with another marker.
Cite this article:
Yudith Annisa Ayu Rezkitha, Soetjipto Soetjipto, Willy Sandhika, Juniastuti Juniastuti, Budi Utomo, Mohan Ramchandani, Phawinee Subsomwong, Hasan Maulahela, Langgeng Agung Waskito, Maria Inge Lusida, Ricky Indra Alfaray, Yoshio Yamaoka, Muhammad Miftahussurur. Value and Accuracy of Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, and Platelet to Lymphocyte Ratio for Detection High Stage and Metastases of Colorectal Cancer in Indonesia. Research Journal Pharmacy and Technology. 2025;18(11):5258-6. doi: 10.52711/0974-360X.2025.00758
Cite(Electronic):
Yudith Annisa Ayu Rezkitha, Soetjipto Soetjipto, Willy Sandhika, Juniastuti Juniastuti, Budi Utomo, Mohan Ramchandani, Phawinee Subsomwong, Hasan Maulahela, Langgeng Agung Waskito, Maria Inge Lusida, Ricky Indra Alfaray, Yoshio Yamaoka, Muhammad Miftahussurur. Value and Accuracy of Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, and Platelet to Lymphocyte Ratio for Detection High Stage and Metastases of Colorectal Cancer in Indonesia. Research Journal Pharmacy and Technology. 2025;18(11):5258-6. doi: 10.52711/0974-360X.2025.00758 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-11-20
REFERENCES:
1. Marmol I, Sanchez-de-Diego C, Dieste AP, et al. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. International Journal of Molecular Sciences;18. Epub Ahead of Print. 2017. doi: 10.3390/ijms18010197.
2. Waters C. Colorectal cancer: An overview. Pharmaceutical Journal. 2006; 276: 323–326.
3. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019; 144: 1941–1953. https://doi.org/10.1002/ijc.31937
4. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017; 66: 683–691. https://doi.org/10.1136/gutjnl-2015-310912
5. Dharmaji AB, Mappincara, Kusuma MI, et al. Analysis of colorectal cancer survival rate at a single institution. Medicina Clinica Practica. 2021; 4: 100232. https://doi.org/10.1016/j.mcpsp.2021.100232
6. Demb J, Earles A, Martínez ME, et al. Risk factors for colorectal cancer significantly vary by anatomic site. BMJ Open Gastroenterology. 2019; 6: 1–9. https://doi.org/10.1136/bmjgast-2019-000313
7. Du V Van, Lam ND, Tung D Van. Valuating concentration of Cea, Ca 19-9 and some biochemical parameters in patients with colorectal cancer. International Journal of Advances in Nursing Management. 2018; 6: 93. http://dx.doi.org/10.5958/2454-2652.2018.00020.3
8. Lin JS, Perdue LA, Henrikson NB, et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA - Journal of the American Medical Association. 2021; 325: 1978–1997. https://doi.org/10.1001/jama.2021.4417
9. Traverso G, Shuber A, Levin B et al. Detection of APC Mutations in Fecal DNA from Patients with Colorectal Tumors. N Engl J Med. 2002; 346: 311–320. https://doi.org/10.1056/nejmoa012294
10. Lech G, Słotwiński R, Słodkowski M, et al. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World Journal of Gastroenterology. 2016; 22: 1745–1755. https://doi.org/10.3748%2Fwjg.v22.i5.1745
11. Bosch LJW, Carvalho B, Fijneman RJA, et al. Molecular tests for colorectal cancer screening. Clinical Colorectal Cancer. 2011; 10: 8–23. https://doi.org/10.3816/ccc.2011.n.002
12. De Rosa M, Pace U, Rega D, et al. Genetics, diagnosis and management of colorectal cancer (Review). Oncology Reports. 2015; 34: 1087–1096. https://doi.org/10.3892/or.2015.4108
13. Lopes G, Stern MC, Temin S, et al. Early detection for colorectal cancer: ASCO resource-stratified guideline. Journal of Global Oncology. 2019; 2019: 1–22. https://doi.org/10.1200/jgo.18.00213
14. Malekpour H, Heidari MH, Vafaee R, et al. Gene expression analysis of colon high-grade dysplasia revealed new molecular mechanism of disease. Gastroenterology and Hepatology from Bed to Bench. 2018; 11: S111–S117. https://pubmed.ncbi.nlm.nih.gov/30774816
15. Dandachi N, Balic M, Stanzer S, et al. Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients. Journal of Molecular Diagnostics. 2005; 7: 631–637. https://doi.org/10.1016%2FS1525-1578(10)60597-1
16. Huang C, Zhan T, Liu Y, et al. Glycomic profiling of carcinoembryonic antigen isolated from human tumor tissue. Clinical Proteomics. 2015; 12: 1–7. https://doi.org/10.1186/s12014-015-9088-3
17. Xu D, Li X fen, Zheng S, et al. Quantitative real-time RT-PCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients. Journal of Zhejiang University Science B. 2006; 7: 445–451. https://doi.org/10.1631/jzus.2006.b0445
18. Sørensen CG, Karlsson WK, Pommergaard HC, et al. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review. International Journal of Surgery. 2016; 25: 134–144. https://doi.org/10.1016/j.ijsu.2015.11.065
19. Yu Z, Chen Z, Wu J, et al. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis. PLoS ONE. 2017; 12: 1–12. https://doi.org/10.1371/journal.pone.0188139
20. Elessawi DF, Alkady MM, Ibrahim IM. Diagnostic and prognostic value of serum IL-23 in colorectal cancer. Arab Journal of Gastroenterology. 2019; 20: 65–68. https://doi.org/10.1016/j.ajg.2019.05.002
21. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51: 27–41. https://doi.org/10.1016%2Fj.immuni.2019.06.025
22. Tan D, Fu Y, Su Q, et al. Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. Medicine. 2016; 95: e3837. https://doi.org/10.1097%2FMD.0000000000003837
23. Wang J, Li J, Wei S, et al. The Ratio of Platelets to Lymphocytes Predicts the Prognosis of Metastatic Colorectal Cancer: A Review and Meta-Analysis. Gastroenterology Research and Practice 2021; 2021: 9699499. https://doi.org/10.1155%2F2021%2F9699499
24. Huang XZ, Chen WJ, Zhang X, et al. An Elevated Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta-Analysis. Disease Markers. 2017. Epub Ahead of Print. 2017. https://doi.org/10.1155/2017/1053125.
25. Zhang M, Huang XZ, Song YX, et al. High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis. BioMed Research International. 2017. Epub Ahead of Print. 2017 https://doi.org/10.1155/2017/9503025.
26. Gao Y, Wang J, Zhou Y, et al. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Scientific Reports. 2018; 8: 1–9. https://doi.org/10.1038/s41598-018-21048-y
27. Chen CC, Yang SH, Lin JK, et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? Journal of Surgical Research. 2005; 124: 169–174. https://doi.org/10.1016/j.jss.2004.08.013
28. Lumachi F, Marino F, Orlando R, et al. Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer. Anticancer Research. 2012; 32: 985–988. https://pubmed.ncbi.nlm.nih.gov/22399621/
29. Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Annals of Oncology. 2010; 21: 70–77. https://doi.org/10.1093/annonc/mdq168
30. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of Clinical Oncology. 2006; 24: 5313–5327. https://doi.org/10.1200/jco.2006.08.2644
31. Carpelan-Holmstrom, M., Louhimo, J., Stenman, U. H., Alfthan, H., Jarvinen, H., and Haglund C. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumor. Biology. 2004; 25(5–6): 228-234. https://doi.org/10.1159/000081385
32. Miglani RK, Bhateja N, Bhat RS, et al. Diagnostic Role of Platelet Lymphocyte Ratio(PLR) in Pancreatic Head Masses. The Indian Journal of Surgery. 2013; 75: 4–9. https://doi.org/10.1007%2Fs12262-012-0443-6
33. Kurniawan A, Lusikooy R, Mappincara M, et al. The Relationship Between Triple Tumor Marker (Cea, Ca 19-9, and Ca 125) and Colorectal Cancer Metastases At Makassar, Indonesia. International Journal of Medical Reviews and Case Reports. 2020; 4: 1. http://dx.doi.org/10.5455/IJMRCR.colorectal-cancer-indonesia
34. Widhyasih RM, Rahmadhanti SD, Fajrunni’mah R. Carcinoembryonic Antigen (CEA) dan Neutrofil-to-Limfosit Ratio (NLR) sebagai Faktor Prediktif Kanker Kolorektal. Jurnal Ilmu dan Teknologi Kesehatan. 2019; 7: 68–76. https://ejurnal.poltekkesjakarta3.ac.id/index.php/jitek/article/view/223/165
35. Siregar GA, Sibarani H. Comparison of Carcinoembryonic Antigen Levels Among Degree of Differentiation and Colorectal Cancer’s Location in Medan. Open access Macedonian Journal of Medical Sciences. 2019; 7: 3447–3450. https://doi.org/10.3889%2Foamjms.2019.442
36. Hruschak J. Mosby’s Diagnostic and Laboratory Test Reference. 1995. Epub Ahead of Print. 1995. https://doi.org/10.1016/s0001-2092(06)63542-4.
37. Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. Journal of Gastrointestinal Oncology. 2016; 7: E45–E51. https://doi.org/10.21037/jgo.2016.01.05
38. Yang A-P, Liu J-P, Tao W-Q, et al. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. International immunopharmacology. 2020; 84: 106504. https://doi.org/10.1016/j.intimp.2020.106504
39. Kalli S, Semine A, Cohen S, et al. American joint committee on cancer’s staging system for breast cancer, eighth edition: What the radiologist needs to know. Radiographics. 2018; 38: 1921–1933. https://doi.org/10.1148/rg.2018180056
40. Finger PT. Cancer staging. Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition. 2014; 69–75. https://link.springer.com/book/10.1007/978-3-642-40489-4
41. Shabo I. Macrophage antigen expression in breast and colorectal cancers A consequence of macrophage - tumour cell fusion ?. Doctoral thesis. 2009. Available at: https://www.diva-portal.org/smash/record.jsf?pid=diva2%3A310555&dswid=-207
42. Irani S. Emerging insights into the biology of metastasis: A review article. Iranian Journal of Basic Medical Sciences. 2019; 22: 833–847. https://doi.org/10.22038%2Fijbms.2019.32786.7839
43. Bin-Bin Su, Shi H, Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World Journal of Gastroenterology. 2012; 18: 2121–2126. https://doi.org/10.3748%2Fwjg.v18.i17.2121
44. Ishizuka D, Shirai Y, Sakai Y, et al. Colorectal carcinoma liver metastases: Clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels. International Journal of Colorectal Disease. 2001; 16: 32–37. https://doi.org/10.1007/s003840000268
45. Thomas P, Forse RA, Bajenova O. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clinical and Experimental Metastasis. 2011; 28: 923–932. https://doi.org/10.1007/s10585-011-9419-3
46. Qi J, Qian C, Shi W, et al. Alu-based cell-free DNA: A potential complementary biomarker for diagnosis of colorectal cancer. Clinical Biochemistry. 2013; 46: 64–69. https://doi.org/10.1016/j.clinbiochem.2012.08.026
47. Kotzev AI, Draganov P V. Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing?. Gastrointestinal Tumors. 2018; 5: 1–13. https://doi.org/10.1159/000488240
48. Posner MR, Mayer RJ. The use of serologic tumor markers in gastrointestinal malignancies. Hematology/oncology clinics of North America. 1994; 8: 533–553. https://pubmed.ncbi.nlm.nih.gov/8707771/
49. Feng F, Tian Y, Xu G, et al. Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017; 17: 737. https://doi.org/10.1186%2Fs12885-017-3738-y
50. Grotowski M. Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2002; 12: 77–80. https://pubmed.ncbi.nlm.nih.gov/11957811/
51. Dong H, Tang J, Li LH, et al. Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases. Asian Pacific Journal of Cancer Prevention. 2013; 14: 909–913. https://doi.org/10.7314/apjcp.2013.14.2.909
52. Wu Z, Kuntz AI, Wadleigh RG. CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer. Clinical Advances in Hematology and Oncology : H and O. 2013; 11: 50–52. https://pubmed.ncbi.nlm.nih.gov/23416865/
53. Kim J-E, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. Journal of Gastroenterology and Hepatology. 2004; 19: 182–186. https://doi.org/10.1111/j.1440-1746.2004.03219.x
54. Coban E, Samur M, Bozcuk H, et al. The value of CEA and CA 19-9 in detecting cancer in a group of high-risk subjects with gastrointestinal symptoms. The International Journal of Biological Markers. 2003; 18: 177–181. https://doi.org/10.1177/172460080301800304
55. Baranyai Z, Krzystanek M, Jósa V, et al. The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer. Thrombosis and Haemostasis. 2013; 111: 483–490. https://doi.org/10.1160/th13-08-0632
56. Ward WH, Goel N, Ruth KJ, et al. Predictive value of leukocyte- and platelet-derived ratios in rectal adenocarcinoma. Journal of Surgical Research. 2018; 232: 275–282. https://doi.org/10.1016/j.jss.2018.06.060